$104.38 +0.33 (0.31%)

BioNTech SE American Depositary Share (BNTX)

Payout Frequency

Dividend History

Pay DateAmountEx-DateRecord Date
June 17, 2022$2.132022-06-022022-06-03

Dividends Summary

Company News

Human Combinatorial Antibody Libraries Market to Surge USD 189.57 Million by 2034, Reports Towards Healthcare
GlobeNewswire Inc. • Towards Healthcare • October 24, 2025

The global human combinatorial antibody libraries market is projected to grow from USD 122 million in 2025 to USD 189.57 million by 2034, with a 5.04% CAGR, driven by increasing demand for advanced medical technologies and therapeutic antibody research.

Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead
The Motley Fool • Prosper Junior Bakiny • October 8, 2025

Two innovative biotech companies, CRISPR Therapeutics and BioNTech, show significant potential for growth through promising drug pipelines and breakthrough medical technologies in gene editing and oncology.

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
Benzinga • Prnewswire • September 18, 2025

The global cell therapy market is projected to grow from $5.88 billion in 2024 to $44.39 billion by 2034, driven by rising demand for regenerative medicine, advancements in biotechnology, and increasing prevalence of chronic diseases.

Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive
Investing.com • Christine Short • June 18, 2025

While smaller deals have been completed, including overseas acquisitions, the expected surge in large-scale mergers and acquisitions has not materialized. Factors like trade policy uncertainty and economic concerns have kept corporate decision-makers cautious about striking major deals.

Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do? - Zacks Investment Research
Zacks Investment Research • N/A • July 24, 2024

Pfizer is expected to report Q2 2024 earnings on July 30, with consensus estimates of $13.22 billion in sales and $0.45 per share. While COVID-19 product sales are expected to decline, key non-COVID drugs like Prevnar, Vyndaqel, and Eliquis are likely to provide top-line support. The company's recent acquisitions and new product launches are also...